Bone-forming stem cells grown on a mesh of these nanowires transform into mature bone much faster than is typical of other culturing conditions.
PATAS, part of a new class of antidiabetic drugs, can correct the metabolic abnormalities leading to type 2 diabetes and its associated comorbidities.
The drug candidate uses a molecule found in the venom of the K’gari funnel-web spider, and can potentially prevent damage caused by heart attacks and stroke.
Scientists have shown that an existing drug may reduce damage after spinal cord injury (SCI), by blocking the inflammatory response in the spinal cord.
AuriNovo is a patient-specific, living tissue implant created using 3D-bioprinting technology for surgical reconstruction of the outer ear in people born with microtia.
Liver4Life reports the successful treatment of a damaged human liver for three days outside of the body, with implantation of the recovered organ into a cancer patient.
Neurological disorders like Parkinson's, chronic depression and other psychiatric conditions can now be managed at home.
COVID-19 has forced Australia's pharmaceutical and healthcare companies to completely redesign how clinical trials are run.
Knowing how pain impulses are inhibited by tricyclic antidepressants is expected to lead to new and improved treatment options.
Biobanking and assisted reproduction could become a reality for koalas by leveraging the existing technology used to help humans conceive.
Overall, the treatment reduced the number of breathing pauses and promoted oxygenation during the night.
It is one thing to invest into pure research, but to invest in a future that has, at its core, collaboration and accelerated development is a giant leap.
A year ago, we were waiting for the federal government to deliver funding and a plan forward for a genetic medicine ecosystem.
Scientists created a method of delivering drugs into human cells using large biological molecules by first encasing them in a protein-based microdroplet.
Researchers are looking for 114 healthy people aged 18–70 living in Victoria to roll up their sleeves for a Phase 1 clinical trial of two Melbourne-made COVID-19 vaccines.